Source: FierceBiotech Biotech IPOs are faring well this fall. That’s despite tough talk from U.S. politicians on biopharma pricing, as the topic has become a focal point in the presidential elections. In a second IPO of the week, Myovant Sciences ($MYOV) raised a larger-than-expected offering after it priced at the…...